ASTX660 mesylate is a novel potent IAP antagonist that targets the BIR3 domain of cIAP1/2 and XIAP with IC50 of 12 nM and <40 nM.
ASTX660 potently inhibits association between XIAP and caspase 9 in HEK293 cell line with EC50 of 2.8 nM, binds to and leads to the degradation of cIAP1/2 and stabilisation of NIK in cell.
ASTX660 induces apoptosis in MDA-MB-231 cells with EC50 of 1.8 nM, which is TNF-α-dependent.
ASTX660 inhibits tumor growth in mice bearing breast and melanoma tumor xenografts.
